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STUDY PROTOCOL Open Access
Core Outcome Set for GROwth restriction:
deVeloping Endpoints (COSGROVE)
Patricia Healy1,2* , Sanne Gordijn3, Wessel Ganzevoort4, Irene Beune3, Ahmet Baschat5, Asma Khalil6,
Louise Kenny7, Frank Bloomfield8, Mandy Daly9, Aris Papageorghiou6,10† and Declan Devane1,2†
Abstract
Background: Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined
growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal
compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems,
including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing
and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare
because of differences in the selection and definition of outcomes. To enable future trials to measure similar,
meaningful outcomes, we are developing two core outcome sets (COS) – one for prevention and the other for
treatment of FGR.
Methods: We will review the literature to identify previously reported outcomes. An international panel of relevant
stakeholders who have experience of FGR (parent or carer of a baby that was growth restricted, health professional
involved in the care of mothers and babies affected by FGR, a person with expertise in FGR research) will rate the
importance of each of those outcomes in a series of three sequential online rounds of a Delphi study. Participants
will be able to add items to the proposed list in round 1. A final face-to-face consensus meeting will be held with
representatives of each stakeholder group at which a final list of outcomes for inclusion in the COS will be agreed.
Discussion: The development of COSs in FGR will ensure the collection and reporting of a minimum dataset agreed
by stakeholder consensus and will reduce inconsistencies in the reporting of outcomes across relevant trials. Such
standardisation in the reporting of outcomes will improve synthesis of evidence and generalisability of knowledge in
the future by reducing heterogeneity in outcomes between trials and thus improve the results of systematic reviews
and meta-analyses. Ultimately, we hope that the COSs will lead to an improvement in the quality of evidence-based
clinical practice, enhance patient care, and improve the quality and consistency of research.
Trial registration: Not applicable. This study is registered in the Core Outcome Measures for Effectiveness (COMET)
database.
Keywords: Core outcome sets, Delphi, Methodology, Foetal growth restriction, Pregnancy
Background
Several factors adversely influence foetal growth, including
maternal disease, problems with establishment of the
utero-placental circulation in early pregnancy, maternal nu-
tritional deprivation, chromosomal and other abnormalities
in the foetus and/or placenta, pregnancy-related medical
conditions such as gestational diabetes and pre-eclampsia,
and exposure to adverse environmental conditions such as
high altitude, toxins including smoking, drugs and other te-
ratogens, infections and foetal metabolic diseases [1, 2]. It
is well recognised that foetuses with foetal growth res-
triction (FGR) are at increased risk of stillbirth, foetal
compromise, early neonatal death and neonatal morbidity
[3, 4]. Evidence is increasing that exposure to an adverse
foetal nutritional environment also causes lifelong changes
in the risk profile for metabolic disease, neurodevelopment
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and cardiac disease [5, 6], also observed in gene expression,
with increased risk of later metabolic diseases seen in neo-
nates born both small- and large-for-gestational-age [7].
Although the heterogeneity of pathologies leading to
FGR results in a wide range of perinatal prognoses, out-
comes differ between the underlying causes. Ultrasound
identification of foetuses with abnormal growth is often
based on a single size parameter, such as abdominal cir-
cumference, or a single (but composite) measure of esti-
mated foetal weight [8]. Small-for-gestational-age babies
are usually defined as estimated foetal weight or abdom-
inal circumference below the 10th percentile on a foetal
size chart. Nevertheless, current tests do not distinguish
well between foetuses at risk of death due to a patho-
logic process (i.e. the growth restricted foetuses) from
foetuses that are small but are otherwise likely to experi-
ence good perinatal outcomes without medical interven-
tion. Single size parameters also fail to detect foetuses
experiencing FGR later in pregnancy that may still be in
the ‘healthy’ range (for example, foetuses that were des-
tined to be on the 50th centile for size but are actually
on the 15th) thus not small-for-gestational-age but
nevertheless still FGR.
Doppler and other functional studies have proven useful
in identifying small foetuses at preterm gestations at risk
of demise [9]; however, the utility of these tests at later
gestation (after 32 weeks) is more limited [10]. Recently, a
consensus definition for both early and late FGR was de-
veloped that incorporated biometrical as well as functional
parameters in which foetuses with measurements above
the 10th percentile may be diagnosed as FGR [11].
Antenatal care has foetal growth monitoring as a cen-
tral aim in order to identify pregnancies with poor
growth that may benefit from surveillance of foetal
well-being; this is based on the premise that timely inter-
vention in response to evolving foetal compromise can
improve outcomes. Screening for growth restriction in
pregnancy may target detection of pregnancies at risk of
poor growth or later in pregnancy when growth restric-
tion has occurred, with the aim of preventing stillbirth.
Effective preventative interventions in women at risk of
growth restriction detected early in pregnancy are few,
with aspirin currently recommended for clinical use in a
subgroup of women at high risk of pre-eclampsia or
FGR due to failure of spiral artery remodelling (placental
insufficiency due to maternal vascular malperfusion)
prior to 16 weeks’ gestation [12] and women who smoke
being supported to cease [13]. Later in pregnancy, ante-
natal corticosteroids and planned early delivery has the
potential to avert stillbirth and prematurity-related risks,
although moderate to late preterm babies are still at risk
of neonatal and longer-term complications [14, 15].
Clinically important outcomes potentially relevant to
FGR are diverse and include both maternal and foetal
outcomes. However, there is heterogeneity in the out-
comes measured and reported in studies evaluating the
effects of interventions for the prevention and treatment
of FGR [16–18]. Such heterogeneity limits the ability of
clinicians, researchers and reviewers to compare, con-
trast and synthesise information on similar interventions
for similar populations across studies. One of the sug-
gested ways to address this is to develop and apply agreed
standardised sets of outcomes, known as ‘core outcome
sets’ (COS). A COS is a minimum set of agreed, standar-
dised outcomes to be measured and reported worldwide
in all trials on a specific condition [19]. This minimises
the substantial heterogeneity in choice of outcome mea-
sures, allowing the efficient comparison and synthesis of
trials [20]. and encourages a more complete reporting of
outcomes, which limits reporting bias [21].
Objective
To develop COSs for prevention and management of FGR.
Methods
The design of this COS project will be guided by The Core
Outcome Set-STAndards for Development (COS-STAD).
A step-wise refinement approach will be used, consisting
of four discrete, yet complementary, sub-work packages
(sWP), whereby each sWP will inform the next sWP.
– sWP1: A comprehensive review to identify reported
outcomes in FGR studies
– sWP2: Development, through an online Delphi
consensus process, of two preliminary COSs for
interventions for the (1) prevention and (2)
treatment of FGR.
– sWP3A: Face-to-face consensus meeting to discuss
and agree on the final FGR COSs;
– sWP4: Development of a dissemination and
implementation strategy for the final (1) prevention
and (2) treatment of FGR COSs
sWP1: A comprehensive review to identify reported
outcome measures in clinical trials in FGR
Objective
To conduct a review of all the mentioned outcomes in
FGR studies in 1994, 2004 and 2014 to identify what has
been reported. The conduct of the review will adhere to
standard searching and selection strategies.
Inclusion criteria
 Participants: pregnant women with or at risk of
having a growth restricted foetus or growth
restricted newborn.
 Any study that investigated risk factors, diagnosing,
prevention, treatment, follow-up or any other aspect
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of FGR. We will exclude case reports, studies that
do not concern FGR, letters to the editors, commen-
taries, expert opinion reviews and animal studies.
 All outcomes reported in the included FGR studies
will be collected.
Search methods for identification of studies
A comprehensive search for published literature on FGR
will be conducted in the Cochrane Central Database,
PubMed and MEDLINE/EMBASE electronic databases.
The combinations of keywords and terms that will be
used in the search are Major MeSH and MeSH on foetal
or intrauterine growth restriction or retardation and
small for gestational age in the title. Our final search is:
((fet* OR foet*) OR (intra-ut* OR intraut*)) AND
((grow* AND (rest* OR retard*)) OR (SGA OR small for
gestational age OR FGR OR IUGR) with filters for Lan-
guage (English) and Search field (title). Articles from Jan
1 until December 31, 1994, from Jan 1 until December
31, 2004, and from Jan 1 until December 31, 2014, will
be selected.
Data collection and management
A purposively developed data abstraction form will be
used to collect the relevant data, i.e. the key characteris-
tics of the eligible studies and the reported outcomes.
The identified records will be assessed by two reviewers
according to the criteria above. Disagreement between
reviewers on abstracted data will be resolved by reading
the full text or, if necessary, by group discussion. The re-
ported outcomes will include both those that are men-
tioned as being measured in the methods section of the
relevant study report or record, and those for which
findings are presented. Outcomes will be categorised per
type of intervention under evaluation (i.e. screening, pre-
vention or treatment intervention), and whether they are
primary or secondary. Where studies focus on more
than one intervention type, outcomes will be extracted
according to type of intervention that the outcome is be-
ing reported for. Where this is not clear from the study,
the outcome will be extracted into a separate column ti-
tled ‘uncertain’.
Data analysis
Once data from all included studies have been extracted,
a list of unique outcomes of FGR will be developed.
These outcomes will be categorised in domains, e.g. ma-
ternal outcomes, neonatal outcomes or long-term out-
comes, with subcategories as appropriate. A unique list
of outcomes that are common to both treatment and
prevention will be formed during the analysis phase, and
a separate list will be made for any outcome extracted
into the ‘uncertain’ column during the data extraction
process. These final lists of outcomes will inform sWP2.
sWP2: Development of a preliminary COS for use in the
(1) prevention and (2) treatment of FGR
Objective
Using the outcomes identified by sWP1, an online, elec-
tronic Delphi method will be used for developing the
preliminary FGR COSs in sWP2.
Delphi procedure
The Delphi method facilitates a means of consensus
building by using a series of sequential questionnaires to
collect data from a panel of experts, service users and
other stakeholders on the topic under investigation, and
has been used previously in COS development [22]. Ori-
ginally developed by the RAND Corporation to come to
consensus on warfare technology in the 1950s, the Del-
phi process is iterative and based on the scoring of a
series of structured statements that are revised, fed back
to the participants and repeated in multiple rounds, in
increasing detail, until consensus has been reached [23].
Recruitment of Delphi participants
The target population reflects the perspectives of a var-
iety of stakeholders in FGR studies. Purposeful sampling
to approach people with informed opinions or known
expertise in FGR will be used. Those potential partici-
pants will be asked to forward the invitation to others
whom they regard as having the required expertise,
thereby facilitating snowball sampling. We will invite
women and their partners as users of maternity services,
midwives, obstetricians, paediatricians/neonatologists,
family doctors, policymakers and groups with specific
expertise/interest in FGR care and perinatal research.
The target sample will be accessed through mass invita-
tional emails, electronic discussion lists and professional
organisations. For example,
 Colleges of Obstetricians and Gynaecologists (UK,
Australia, Canada, Netherlands, Germany)
 College of Physicians
 Cochrane Pregnancy & Childbirth Reviewers’ Group
 Cochrane Pregnancy & Childbirth consumer
networks
 European Perinatal Epidemiology Network
 Association for Improvements in Maternity Services
(Ireland and UK)
 European Network of Childbirth Associations
 European Midwives Association
 The International Society of Ultrasound in
Obstetrics & Gynecology
 Perinatal societies
 Patient groups such as SANDS, INHA, MUMSnet,
the Dutch HELLP foundation and VOC (parents of
incubator children)
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Note that this list is not exhaustive; rather, it merely
provides some examples of e-discussion lists that might
be accessed.
We will also invite those who have participated in pre-
vious work in this area and other experts in FGR who
have published on FGR as identified in sWP1. We will
ask all potential participants to suggest colleagues who
should be in the Delphi panel, aiming for international
coverage of the Delphi panel.
Recruitment of users of maternity services will be via
the electronic discussion e-mail list manager. The man-
ager (or chairperson of the group, details of which are
publicly available on the websites of the groups listed
above) will be emailed with information on the survey
and a request to distribute an invitation email to mem-
bers on their email lists. The list managers will have an
opportunity to contact the researchers directly to clarify
any issues or to seek further information about the sur-
vey and the research prior to deciding. The distribution
of the survey, ultimately, will be at the discretion of the
email list manager. There is precedent for survey distri-
bution on matters related to maternity care by these
groups (for example, http://www.irishhealth.com/arti-
cle.html?id=23473). The recruitment of users of mater-
nity services will be guided by a maternity service user
who sits on our working group and acts as our patient
and public involvement research partner.
An invitation e-mail will be circulated to potential and
suitable Delphi participants. We will provide every po-
tential participant with an explanatory email and a video
in which the need for the study, as well as what partici-
pation involves and why it is important, will be ex-
plained. We will explain the principles of a COS as a
minimum set of outcomes that are mandatory to report
in future studies (the difference between ‘core’ outcome
and ‘desired’ outcomes). Individuals who wish to partici-
pate will be asked to click on a link that will enable them
to register with the DelphiManager software system,
which we are using for this study. On receipt of this, the
researcher will forward further information, instructions
and the round 1 survey instrument, which is accessible
only after the potential participant has indicated their
formal consent. We will ask all respondents to forward
the invitation email to other potential participants who
might be interested in the study.
Data collection and analysis
An online Delphi with a series of three sequential
rounds is planned. Questionnaires will be completed
using DelphiManager, which is a web-based system de-
signed to facilitate the building and management of Del-
phi surveys. In each round, panel members will receive
an e-mail with a unique link to the questionnaire. Re-
sponses to each round will be collated, analysed, and
redistributed to participants with their individual response
to each item for further comment in successive rounds.
Each participant will also be shown the proportion of par-
ticipants within each stakeholder group that rated the out-
come at each of the 1–9 points on the rating scale.
Each round will have a response closing date 21 days
after the date of distribution of the survey. Responses
will be monitored and an e-mail reminder will be sent to
anyone who has not responded by day 14, with a final
reminder after 19 days. The number of participants
completing each round and attrition across rounds will
be documented.
Within the Delphi process, ratings of all panel mem-
bers are weighed equally within their own stakeholder
category. Panel members who did not enter a round will
not be invited for subsequent rounds.
First round
The first-round instrument will contain the rating in-
strument with outcomes identified in the review (sWP1)
and a short questionnaire seeking participant demo-
graphic data. Each outcome will have an associated plain
English definition. We will group our outcomes under
relevant domains such as maternal, foetal, neonatal,
physiological, mortality, functioning, etc. To ensure
completeness of outcomes, participants in this round
will also be invited to add up to two further ‘new’ out-
comes that they would consider important or relevant
for inclusion in either the prevention or treatment of
FGR COSs.
The panel will be asked to rate the outcomes for FGR
prevention and treatment on a 9-point Likert-scale. Typ-
ically, 1–3 signifies an outcome is of limited importance,
4–6 important but not critical, and 7–9 critical [22]. We
will also include an ‘unable to score’ category to allow an
option for participants who may feel that they do not
have the level of expertise to score certain outcomes.
Second round
The second-round instrument will contain all outcomes
from round 1. Only those participants who have com-
pleted the first round will be invited to participate in
round 2. All additional outcomes suggested by at least
two participants and not already included in round 1 will
be included in round 2. For each outcome from round 1,
the rating results (i.e. the proportion of participants rat-
ing each point on the 9-point rating scale) from each
stakeholder group (maternity service users, midwives,
obstetricians, paediatricians/neonatologists, and groups
with expertise in FGR and research) will be presented
numerically in the form of proportions within Delphi-
Manager. Proportions will be produced for each stake-
holder group separately. In addition, each participant
will be able to see their individual round 1 score, which
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they may compare against the distribution of responses
for their respective stakeholder group and the other
stakeholder groups. Participants will be asked to re-rate
the importance of each outcome with knowledge of their
and other group’s previous ratings. In addition, partici-
pants will be asked to rate the newly identified outcomes
from round 1. All ratings will use the same Likert-type
scale that was used in round 1. The round 2 Delphi in-
strument will contain a question asking the participant
about their willingness and availability to attend the sub-
sequent face-to-face consensus meeting.
Third round
In round 3, participants who completed round 2 will be
presented with the outcomes from round 2 that were
rated as critical (7–9 on Likert scale) for inclusion in the
COSs by at least 70% of all respondents and those rated
as of limited importance (1–3 on Likert scale) by 15% or
less of all respondents. Each retained outcome will be
presented as in round 1. Participants will be asked to
re-rate the retained outcomes from round 2 using the
same Likert-type scale that was used in rounds 1 and 2.
All outcomes judged ‘consensus in’ and those judged
neither ‘consensus in’ nor ‘consensus out’ (Table 1) will
be taken forward to the face-to-face consensus meeting.
sWP3: Consensus meeting
Objective
Consensus on the final (1) prevention and (2) treatment
of FGR COSs will be achieved through a face-to-face
meeting with representatives of key stakeholders in FGR
clinical care and research.
Participants
Participants for the meeting will be selected from Delphi
completers who indicated that they were interested in
attending. The consensus group will include, at a mini-
mum, three of all stakeholder groups (maternity service
users, midwives, obstetricians, paediatricians/neonatolo-
gists, and groups with expertise in FGR and research).
Schedule
A full-day meeting is proposed. Materials will be distrib-
uted in advance of the meeting date with the intention
that participants may consider these individually, but not
with others within or outside of their stakeholder group
(i.e. participants will be actively discouraged from discuss-
ing these materials with others in advance of the meeting).
To achieve effective consensus, the facilitator will ensure
that the meeting is (1) collaborative, (2) cooperative and
non-competitive, and (3) inclusive with equal input from all
participants. The purpose of the meeting will be discussed,
i.e. to finalise the core outcomes for each of the COSs. All
outcomes judged ‘consensus out’ in the Delphi rounds will
be presented as a set. The group will be asked if they sup-
port the removal of these outcomes. Next, all outcomes
judged ‘consensus in’ will be presented individually and
the group asked, following discussion, to vote whether the
outcome should be included in the respective COS. Fi-
nally, all outcomes that are judged neither ‘consensus in’
nor ‘consensus out’ will be discussed individually and the
group will vote whether the outcome should be included.
sWP4 dissemination and implementation strategy
Developing and agreeing on a COS for use in studies on a
specific condition provides for effective outcome measure-
ment in studies, and for synthesis of evidence in system-
atic reviews, and should reduce waste in research [22, 24].
However, for a COS to be truly beneficial, it must be used
in all studies on a given condition, where appropriate. For
this to occur, wide dissemination of the developed COS is
required. COS developers are recommended to consider
engagement with the relevant Cochrane Review Groups,
clinical guideline developers, research funders, journal edi-
tors, regulators such as research ethics committees, and
trial registries. The CROWN initiative, led by journal edi-
tors, in resolving to harmonise outcome reporting in
women’s health research, supports the implementation of
COSs. This sWP will develop a detailed dissemination and
implementation strategy to ensure effective dissemination
of the final FGR COSs, to raise awareness of the developed
COSs and to encourage their use in future studies in FGR.
Discussion
Although there is an extensive list of planed/ongoing and
completed COSs in the ‘pregnancy and childbirth’ health
area on the Core Outcome Measures for Effectiveness in
Trials (COMET) website (www.comet-initiative.org/
Table 1 Consensus classification
Consensus classification Description Definition
Consensus in Consensus that outcome should
be included in the core outcome set
70% or more participants scoring as 7
to 9 AND < 15% participants scoring as 1 to 3
Consensus out Consensus that outcome should
not be included in the core outcome set
70% or more participants
scoring as 1 to 3 AND < 15% of participants
scoring as 7 to 9
Neither consensus in nor out (no consensus) Uncertainty about importance of
outcome so retain for next round
Anything else
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studies/search), there is currently no published COS for
FGR. We acknowledge the potential for overlap between
some outcomes in this COS and other COSs such as pre-
term birth, stillbirth and pre-eclampsia, but believe that a
separate COS for FGR, and for other conditions, is valuable
and necessary. We propose the development of two COSs
(prevention and treatment) to be measured in future stud-
ies on pregnancies complicated by FGR. The development
of COSs in FGR will ensure the collection and reporting of
a minimum dataset agreed by stakeholder consensus and
will reduce inconsistencies in the reporting of outcomes
across relevant trials. Such standardisation in the reporting
of outcomes will improve the synthesis of evidence and
generalisability of knowledge in the future by reducing het-
erogeneity between trials and thus improve the results of
systematic reviews and meta-analyses.
The methodology we have chosen (selection of partici-
pants, Delphi rounds, consensus meeting) is based on
methods successfully used in previously developed COSs.
The COS process using the Delphi method is a widely ac-
cepted methodology. However, it must be acknowledged
that the methods used lack a robust evidence base for all
components. According to Gargon et al. ([25], p. 141), the
concept of a COS is still being established, and little is
known about what should inform developers’ methodo-
logical choices. The credibility of a COS depends on the use
of sound methodology; we will consider the potential impact
of our methodological decisions in our final study report.
This COS will identify outcomes to be measured
(‘what’ to measure). We acknowledge that further work
will be needed to identify the tools, timing, etc. required
to measure outcomes in the COS (‘how’ to measure).
We acknowledge that it will be necessary for us to limit
our search to English papers as we do not have the re-
sources for translating non-English papers and recognise
this as a potential limitation.
Inviting relevant stakeholders who have experience of
FGR (for example, parent or carer of a baby that was
growth restricted, health professional involved in the
care of mothers and babies affected by FGR, a person
with expertise in FGR research) to take part in this study
will ensure that the resulting COS has broad consensus,
is relevant and is wide reaching.
Ultimately, we hope that the standardisation in trial
outcomes will lead to an improvement in the quality of
evidence-based clinical practice, enhance patient care
and improve the quality and consistency of research.
Project status
The review of the literature is complete and the list
of outcomes for the round 1 Delphi has been com-
piled. We are currently preparing to recruit partici-
pants to the Delphi study. The final COS is expected
by August 2018.
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